We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down
Read MoreHide Full Article
Orthofix Medical Inc. (OFIX - Free Report) reported second-quarter 2019 adjusted earnings per share (EPS) of 28 cents, down 33.3% year over year. The figure missed the Zacks Consensus Estimate by 30%.
Reported loss per share in the quarter came in at 3 cents, showing a sharp year-over-year decline from the year-ago quarter’s EPS of 5 cents.
Revenues in the second quarter came in at $115.9 million, up 3.9% year over year and up 5% at constant exchange rate or CER. The figure was almost in line with the Zacks Consensus Estimate.
Segmental Analysis
The company’s key operating segment Orthofix Spine comprises product lines like Bone Growth Therapies, Spinal Implants, Biologics and Orthofix Extremities. For the quarter under review, revenues from Bone Growth Therapies totaled $50.1 million, up 3.9% year over year both on a reported and CER basis.
ORTHOFIX MEDICAL INC. Price, Consensus and EPS Surprise
Spinal implants raked in revenues of $23.2 million, down 2.7% (2% at CER). Biologics recorded revenues of $16.7 million, up 14.2%, both on a reported and CER basis. Revenues from Orthofix Extremities grossed $25.8 million, up 4% on a reported basis (8.5% at CER).
Margin Details
In the second quarter of 2019, gross profit increased 1.5% year over year to $90 million. However, gross margin contracted 181 basis points (bps) to 77.7%. Adjusted operating profit declined 69.2% from the year-ago quarter to $2.3 million. The decline was led by a 7.9% year-over-year increase in operating expenses. As a result, operating margin contracted 463 bps to 1.95%.
Operational Update
Orthofix exited the second quarter of 2019 with cash equivalents of $52.1 million compared with $46.7 million in the preceding quarter. Year to date net cash from operating activities totaled $8.3 million, down 35.9% from the year-ago $13 million. Capital expenditures totaled $10.3 million in the first six months of 2019, up from $6.7 million in the year-ago period.
Guidance for 2019
Orthofix kept the 2019 financial guidance unchanged. Adjusted EPS at the end of 2019 is projected in the band of $1.75-$1.82. The Zacks Consensus Estimate of $1.78 is within the guidance. Revenues are projected in the band of $472-$477 million. The Zacks Consensus Estimate of $472.8 million is just above the low end of the guidance.
Our Take
Orthofix ended the second quarter of 2019 on a mixed note. Barring Implants, all key operating segments witnessed year-over-year revenue growth. Though gross profit increased in the quarter, the contraction in gross and operating margin is concerning. On a positive note, the recent FDA approval of the M6-C Artificial Cervical disc buoys optimism.
Zacks Rank and Key Picks
Orthofix currently carries a Zacks Rank #3 (Hold).
A few better-ranked companies which have come up with solid results this earnings season are Surmodics, Inc. (SRDX - Free Report) , Baxter International Inc. (BAX - Free Report) and Zimmer Biomet Holdings, Inc. (ZBH - Free Report) .
Surmodics delivered third-quarter fiscal 2019 adjusted EPS of 15 cents which surpassed the Zacks Consensus Estimate by a whopping 200%. Revenues of $24.3 million exceeded the Zacks Consensus Estimate by 6.6%. The company carries a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Baxter delivered second-quarter 2019 adjusted EPS of 89 cents, which surpassed the Zacks Consensus Estimate of 81 cents by 9.9%. Revenues of $2.84 billion also beat the Zacks Consensus Estimate of $2.79 billion by 1.9%. The company holds a Zacks Rank #2 (Buy).
Zimmer Biomet reported second-quarter 2019 adjusted EPS of $1.93, which beat the Zacks Consensus Estimate by a penny. Moreover, revenues totalled $1.99 billion, topping the Zacks Consensus Estimate of $1.98 billion by a slight margin. The company is also Zacks #2 Ranked.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down
Orthofix Medical Inc. (OFIX - Free Report) reported second-quarter 2019 adjusted earnings per share (EPS) of 28 cents, down 33.3% year over year. The figure missed the Zacks Consensus Estimate by 30%.
Reported loss per share in the quarter came in at 3 cents, showing a sharp year-over-year decline from the year-ago quarter’s EPS of 5 cents.
Revenues in the second quarter came in at $115.9 million, up 3.9% year over year and up 5% at constant exchange rate or CER. The figure was almost in line with the Zacks Consensus Estimate.
Segmental Analysis
The company’s key operating segment Orthofix Spine comprises product lines like Bone Growth Therapies, Spinal Implants, Biologics and Orthofix Extremities. For the quarter under review, revenues from Bone Growth Therapies totaled $50.1 million, up 3.9% year over year both on a reported and CER basis.
ORTHOFIX MEDICAL INC. Price, Consensus and EPS Surprise
ORTHOFIX MEDICAL INC. price-consensus-eps-surprise-chart | ORTHOFIX MEDICAL INC. Quote
Spinal implants raked in revenues of $23.2 million, down 2.7% (2% at CER). Biologics recorded revenues of $16.7 million, up 14.2%, both on a reported and CER basis. Revenues from Orthofix Extremities grossed $25.8 million, up 4% on a reported basis (8.5% at CER).
Margin Details
In the second quarter of 2019, gross profit increased 1.5% year over year to $90 million. However, gross margin contracted 181 basis points (bps) to 77.7%. Adjusted operating profit declined 69.2% from the year-ago quarter to $2.3 million. The decline was led by a 7.9% year-over-year increase in operating expenses. As a result, operating margin contracted 463 bps to 1.95%.
Operational Update
Orthofix exited the second quarter of 2019 with cash equivalents of $52.1 million compared with $46.7 million in the preceding quarter. Year to date net cash from operating activities totaled $8.3 million, down 35.9% from the year-ago $13 million. Capital expenditures totaled $10.3 million in the first six months of 2019, up from $6.7 million in the year-ago period.
Guidance for 2019
Orthofix kept the 2019 financial guidance unchanged. Adjusted EPS at the end of 2019 is projected in the band of $1.75-$1.82. The Zacks Consensus Estimate of $1.78 is within the guidance. Revenues are projected in the band of $472-$477 million. The Zacks Consensus Estimate of $472.8 million is just above the low end of the guidance.
Our Take
Orthofix ended the second quarter of 2019 on a mixed note. Barring Implants, all key operating segments witnessed year-over-year revenue growth. Though gross profit increased in the quarter, the contraction in gross and operating margin is concerning. On a positive note, the recent FDA approval of the M6-C Artificial Cervical disc buoys optimism.
Zacks Rank and Key Picks
Orthofix currently carries a Zacks Rank #3 (Hold).
A few better-ranked companies which have come up with solid results this earnings season are Surmodics, Inc. (SRDX - Free Report) , Baxter International Inc. (BAX - Free Report) and Zimmer Biomet Holdings, Inc. (ZBH - Free Report) .
Surmodics delivered third-quarter fiscal 2019 adjusted EPS of 15 cents which surpassed the Zacks Consensus Estimate by a whopping 200%. Revenues of $24.3 million exceeded the Zacks Consensus Estimate by 6.6%. The company carries a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Baxter delivered second-quarter 2019 adjusted EPS of 89 cents, which surpassed the Zacks Consensus Estimate of 81 cents by 9.9%. Revenues of $2.84 billion also beat the Zacks Consensus Estimate of $2.79 billion by 1.9%. The company holds a Zacks Rank #2 (Buy).
Zimmer Biomet reported second-quarter 2019 adjusted EPS of $1.93, which beat the Zacks Consensus Estimate by a penny. Moreover, revenues totalled $1.99 billion, topping the Zacks Consensus Estimate of $1.98 billion by a slight margin. The company is also Zacks #2 Ranked.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>